Precigen Is Still A Buy After The Papzimeos Rally
Source: SeekingAlpha
2025-11-25 06:51:57 ET
Introduction
There have been some notable developments at Precigen, Inc. ( PGEN ) since my last look in mid-August. My Buy rating followed the FDA approval of PAPZIMEOS for adults with recurrent respiratory papillomatosis, or RRP, a rare disease. Recall that Precigen originally pursued accelerated approval. The FDA granted full approval in August with no requirement for a confirmatory trial, inspiring PGEN to rally. I estimated at that time that PAPZIMEOS could generate >$1 billion in peak annual sales. In this light, its valuation of <$1 billion (enterprise value) appeared conservative....
Read the full article on Seeking Alpha
For further details see:
Precigen Is Still A Buy After The Papzimeos Rally
Precigen Inc.
NASDAQ: PGEN
PGEN Trading
-3.48% G/L:
$3.435 Last:
626,494 Volume:
$3.43 Open:
PGEN Latest News
March 11, 2026 04:05:00 pm
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
January 20, 2026 08:05:00 am
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
January 12, 2026 08:00:00 am
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026 04:05:00 pm
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
PGEN Stock Data
$1,632,900,063
187,173,160
1.3%
60
N/A
Biotechnology & Life Sciences
Healthcare
US
Germantown
